MCID: PLM031
MIFTS: 64

Poliomyelitis

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 72 49 55 41 14 69
Infantile Paralysis 49 69
Polio 49 51

Characteristics:

Orphanet epidemiological data:

55
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD10 32 A80 A80.9
ICD9CM 34 045 045.9
MeSH 41 D011051
NCIt 46 C35550
Orphanet 55 ORPHA2912
MESH via Orphanet 42 D011051
UMLS via Orphanet 70 C0032371
ICD10 via Orphanet 33 A80.0 A80.1 A80.2 more

Summaries for Poliomyelitis

NIH Rare Diseases : 49 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected. Last updated: 12/24/2015

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and tetanus, and has symptoms including fever, sore throat and headache. An important gene associated with Poliomyelitis is PVR (Poliovirus Receptor), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Phenol and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include motor neurons, brain and spinal cord, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results_in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted_by ingestion of food or water contaminated with feces, or transmitted_by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 72 Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 34.1 DPT PVR
2 tetanus 30.9 IFNG IL10 IL4
3 rubella 30.4 IL10 IL4 TNF
4 aseptic meningitis 30.2 IFNG IL10 TNF
5 osteomyelitis 30.0 IFNG IL10 TNF
6 neuritis 29.8 IFNG IL4 TNF
7 chlamydia 29.7 IFNG IL10 TNF
8 leprosy 3 29.7 IFNG IL10 IL4 TNF
9 hemophagocytic lymphohistiocytosis 29.7 IFNG IL10 TNF
10 meningitis 29.5 FCGR2A IFNG IL10 TNF
11 conjunctivitis 29.5 ICAM1 IFNG IL4
12 periodontitis 29.5 IFNG IL10 IL4 TNF
13 myasthenia gravis 29.5 IFNG IL10 IL4 TNF
14 mycobacterium tuberculosis 1 29.5 IFNG IL10 IL4 TNF
15 common variable immunodeficiency 29.4 IFNG IL10 IL4 TNF
16 multiple sclerosis 29.1 ICAM1 IFNG IL10 IL4 TNF
17 nonparalytic poliomyelitis 12.4
18 poliomyelitis in patients with immunodeficiencies deemed at risk 11.9
19 bulbar polio 11.7
20 postpoliomyelitis syndrome 11.2
21 spastic diplegia 10.9
22 motor neuron disease 10.9
23 spinal polio 10.9
24 bulbospinal polio 10.9
25 punctate inner choroidopathy 10.5 IL10 TNF
26 microscopic polyangiitis 10.5 IL10 TNF
27 multifocal choroiditis 10.5 IL10 TNF
28 transient hypogammaglobulinemia 10.5 IL10 TNF
29 mycoplasmal pneumonia 10.5 IFNG IL4
30 immunoglobulin a deficiency 1 10.5 IL10 IL4
31 choroiditis 10.5 IL10 TNF
32 scleritis 10.5 IL4 TNF
33 staphylococcal toxic shock syndrome 10.5 IFNG TNF
34 autoimmune myocarditis 10.4 IFNG TNF
35 mucocutaneous leishmaniasis 10.4 IL10 TNF
36 retinitis pigmentosa 22 10.4 IL10 IL4
37 idiopathic achalasia 10.4 IL10 TNF
38 trichuriasis 10.4 IL10 TNF
39 chronic beryllium disease 10.4 IFNG TNF
40 trichosporonosis 10.4 IFNG TNF
41 b-cell growth factor 10.4 IFNG IL4
42 apple allergy 10.4 IL10 IL4
43 beta-lactam allergy 10.4 IL10 IL4
44 penicillin allergy 10.4 IFNG IL4
45 atopic keratoconjunctivitis 10.4 IFNG IL4
46 sporotrichosis 10.4 IFNG IL10
47 immune suppression 10.4 IFNG IL10
48 diphtheria 10.4
49 chronic graft versus host disease 10.4 IFNG IL10
50 nontuberculous mycobacterial lung disease 10.4 LEP TNF

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

Symptoms:

12
  • fever
  • sore throat
  • headache
  • vomiting
  • fatigue
  • neck stiffness
  • muscle spasms
  • acute flaccid paralysis

MGI Mouse Phenotypes related to Poliomyelitis:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 LEP TNF IFNG DLG1 IL10 FCGR2A
2 immune system MP:0005387 10.09 LEP TNF IFNG DLG1 IL10 FCGR2A
3 digestive/alimentary MP:0005381 10.04 TNF LEP IFNG DLG1 IL10 ICAM1
4 endocrine/exocrine gland MP:0005379 10.02 LEP TNF IL4 IFNG DLG1 IL10
5 integument MP:0010771 9.95 LEP TNF IFNG DPT IL10 ICAM1
6 muscle MP:0005369 9.85 LEP TNF IFNG DLG1 IL10 ICAM1
7 no phenotypic analysis MP:0003012 9.73 TNF IL4 IFNG DLG1 IL10 FCGR3B
8 neoplasm MP:0002006 9.72 LEP TNF IFNG IL10 ICAM1
9 respiratory system MP:0005388 9.63 LEP TNF IL4 IFNG DLG1 IL10
10 skeleton MP:0005390 9.56 LEP TNF IFNG DLG1 IL10 FCGR2A
11 vision/eye MP:0005391 9.23 TNF LEP IFNG DLG1 IL10 DPT

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenol Approved, Experimental Phase 4 108-95-2 996
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
4 Zinc sulfate Approved, Investigational Phase 4 7733-02-0
5
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
6
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
7
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Menthol Approved Phase 4 2216-51-5 16666
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 68-26-8, 11103-57-4 445354
11
BCG vaccine Investigational Phase 4,Phase 2
12 Antibodies Phase 4,Phase 2,Phase 3
13 Antibodies, Blocking Phase 4
14 Immunoglobulins Phase 4,Phase 2,Phase 3
15 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Micronutrients Phase 4,Phase 2,Phase 3
18 Trace Elements Phase 4,Phase 2,Phase 3
19 Antioxidants Phase 4,Phase 2,Phase 3
20 Protective Agents Phase 4,Phase 3,Phase 2
21 Retinol palmitate Phase 4,Phase 2,Phase 3
22 Vitamins Phase 4,Phase 2,Phase 3
23 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
24 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
25 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
26 Polymyxin B Phase 4
27 Polymyxins Phase 4
28 Anticoagulants Phase 4,Phase 3,Phase 2
29 Fibrinolytic Agents Phase 4,Phase 3
30 PENTA Phase 4,Phase 3
31 Antidotes Phase 4,Phase 3,Phase 2
32 Calcium, Dietary Phase 4,Phase 3,Phase 2
33 Chelating Agents Phase 4,Phase 3,Phase 2
34 Iron Chelating Agents Phase 4,Phase 3,Phase 2
35 Pentetic Acid Phase 4,Phase 3,Phase 2
36 Analgesics Phase 4,Phase 3
37 Analgesics, Non-Narcotic Phase 4,Phase 3
38 Anti-Inflammatory Agents Phase 4,Phase 2
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Antipyretics Phase 4,Phase 3
41 Antirheumatic Agents Phase 4
42 Cyclooxygenase Inhibitors Phase 4
43 Peripheral Nervous System Agents Phase 4,Phase 3
44 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2
45 retinol Nutraceutical Phase 4,Phase 2,Phase 3
46 Acidophilus Nutraceutical Phase 4
47 Zinc Supplement Nutraceutical Phase 4
48
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 58-14-0 4993
49
Sulfadoxine Approved, Investigational Phase 2, Phase 3,Phase 1 2447-57-6 17134
50
Aluminum hydroxide Approved, Investigational Phase 3,Phase 1,Phase 2 21645-51-2

Interventional clinical trials:

(show top 50) (show all 325)

# Name Status NCT ID Phase Drugs
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
3 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
4 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
5 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
6 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
7 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
8 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
9 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
10 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
11 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
12 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
13 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
14 A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children Completed NCT02521974 Phase 4
15 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
16 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
17 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
18 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
19 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
20 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
21 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
22 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
23 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
24 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
25 Inactivated Influenza Vaccine Effectiveness in Tropical Africa Completed NCT00893906 Phase 4
26 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
27 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
28 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
29 Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV Completed NCT03310073 Phase 4
30 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
31 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
32 Poliovirus Vaccine Trial in Bangladesh Completed NCT01633216 Phase 4
33 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
34 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
35 Different Doses of Vitamin A and Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
36 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
37 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
38 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
39 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
40 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
41 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
42 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
43 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
44 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
45 Influenza Immunization of Children in India Completed NCT01680679 Phase 4
46 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
47 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
48 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
49 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4 Paracetamol;Ibuprofen;Paracetamol;Ibuprofen
50 Duration of IPV Priming and Antibody Decay Recruiting NCT03202719 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

The Foundational Model of Anatomy Ontology organs/tissues related to Poliomyelitis:

18
Motor Neurons

MalaCards organs/tissues related to Poliomyelitis:

38
Brain, Spinal Cord, B Cells, Liver, Bone, Testes, Breast

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 985)
# Title Authors Year
1
Vaccine-associated paralytic poliomyelitis in a patient with acute lymphocytic leukemia. ( 29322435 )
2018
2
Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015. ( 29395524 )
2018
3
Progress Toward Poliomyelitis Eradication - Pakistan, January 2016-September 2017. ( 29166363 )
2017
4
Post-marketing surveillance study to assess the safety and tolerability of an Inactivated Poliomyelitis Vaccine in Indian children. ( 28846490 )
2017
5
'A matter of commonsense': the Coventry poliomyelitis epidemic 1957 and the British public. ( 29118656 )
2017
6
Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016. ( 29240729 )
2017
7
Understanding the Dynamics of Poliomyelitis Spread in Pakistan. ( 28845415 )
2017
8
Poliomyelitis and its management in the hospital of Stara Gora, Slovenia (In memoriam Dr Hilda VeliA8kov). ( 29309180 )
2017
9
Progress towards poliomyelitis eradication: Pakistan, January 2016a89September 2017. ( 29171250 )
2017
10
Reverse Less Invasive Stabilization System (LISS) Plating for Proximal Femur Fractures in Poliomyelitis Survivors: A Report of Two Cases. ( 29138386 )
2017
11
175 Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2017. ( 28387112 )
2017
12
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2016-June 2017. ( 28817551 )
2017
13
Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis. ( 28356537 )
2017
14
Knowledge assessment regarding poliomyelitis among the caregivers of children who received oral polio vaccine reveals lack of awareness of the vaccine vial monitor (VVM): Implications extending beyond polio eradication. ( 28121284 )
2017
15
Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. ( 28604777 )
2017
16
Poliomyelitis eradication a89 the review of notifications from the years 2010-2016 sent to National IHR Focal Point ( 28654739 )
2017
17
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. ( 28362135 )
2017
18
How Long does Denervation Take in Poliomyelitis? Or is it a Lifetime?" ( 29204007 )
2017
19
Negative or positive? The iron lung and poliomyelitis-Zurich, 1951. ( 28675796 )
2017
20
The push to eradicate poliomyelitis in the Eastern Mediterranean Region. ( 29178113 )
2017
21
Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency. ( 28361789 )
2017
22
Acute segmental poliomyelitis-like flaccid paralysis in an adult in the UK, associated with enterovirus D68. ( 28626021 )
2017
23
Virologic monitoring of poliovirus type 2 after OPV2 withdrawal in April 2016: an important advance in eradicating poliomyelitis and eliminating live oral poliovirus vaccines worldwide, 2016a892017. ( 28547947 )
2017
24
Epidemiological Surveillance of Poliomyelitis During the Military and Political Conflict in the Central African Republic, 2013 and 2014. ( 28480271 )
2017
25
A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies. ( 28694346 )
2017
26
Morbidity and mortality following poliomyelitis - a lifelong follow-up. ( 27869331 )
2017
27
Progress towards poliomyelitis eradication: Afghanistan, January 2016a89June 2017. ( 28819963 )
2017
28
The Destructive Power of Circumstance on Concurrent Poliomyelitis and Osteomyelitis. ( 29051879 )
2017
29
Combined tibial lengthening and ankle arthrodesis for patients with certain type of sequelae of poliomyelitis. ( 28117634 )
2017
30
Hybrid repair of abdominal aortic aneurysm in a patient with poliomyelitis-related deformities. ( 29242068 )
2017
31
A case-control study on the association of pulse oral poliomyelitis vaccination and Gianotti-Crosti syndrome. ( 27943306 )
2017
32
Assessment of energy expenditure in individuals with post-poliomyelitis syndrome. ( 28355321 )
2017
33
Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. ( 28057194 )
2017
34
Feasibility of using global system for mobile communication (GSM)-based tracking for vaccinators to improve oral poliomyelitis vaccine campaign coverage in rural Pakistan. ( 28802756 )
2017
35
An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. ( 28549485 )
2017
36
Outcome after cementless total hip arthroplasty for arthritic hip in patients with residual poliomyelitis: a case series. ( 27229169 )
2016
37
Effective case/infection ratio of poliomyelitis in vaccinated populations. ( 26830060 )
2016
38
Pakistan as a major obstacle in global end to poliomyelitis program: background and 2016 update. ( 27527564 )
2016
39
International Health Regulations in practice: Focus on yellow fever and poliomyelitis. ( 27541082 )
2016
40
Poliomyelitis: residual hurdles to global eradication. Commentary. ( 27999213 )
2016
41
Differential preference for pertussis and poliomyelitis vaccines in urban versus rural parents in Guatemala. ( 27095889 )
2016
42
Shoulder arthroplasty for sequelae of poliomyelitis. ( 26700552 )
2016
43
Experiences of attitudes in Sierra Leone from the perspective of people with poliomyelitis and amputations using orthotics and prosthetics. ( 27829289 )
2016
44
The effect of footwear adapted with a multi-curved rocker sole in conjunction with knee-ankle-foot orthoses on walking in poliomyelitis subjects: a pilot study. ( 27982715 )
2016
45
Acute poliomyelitis. By F. E. Batten MD Cantab FRCP Lond. The Lumleian Lectures for 1916 delivered before the Royal College of Physicians. Brain 1916; 39: 115-211. ( 27086871 )
2016
46
Progress Toward Poliomyelitis Eradication - Pakistan, January 2015-September 2016. ( 27880752 )
2016
47
Progress towards poliomyelitis eradication: Afghanistan, January 2015a89August 2016. ( 27811982 )
2016
48
Comparison and Contrast of the Elimination Campaigns for Poliomyelitis and Leprosy: Which is More Feasible? ( 27349781 )
2016
49
A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin-2 vaccine virus. ( 27099315 )
2016
50
Long-term Outcome of Unconstrained Primary Total Hip Arthroplasty in Ipsilateral Residual Poliomyelitis. ( 27841928 )
2016

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 FCGR2A FCGR3A FCGR3B ICAM1 IFNG IL10
2
Show member pathways
12.75 ICAM1 IFNG IL10 IL4 TNF
3
Show member pathways
12.68 ICAM1 IFNG IL4 TNF
4
Show member pathways
12.52 IFNG IL10 IL4 TNF
5
Show member pathways
12.5 IFNG IL10 IL4 TNF
6 12.48 IFNG IL10 IL4 PVR TNF
7
Show member pathways
12.43 FCGR3A FCGR3B ICAM1 IFNG IL4 TNF
8
Show member pathways
12.35 DLG1 IFNG IL10 IL4 TNF
9
Show member pathways
12.28 IFNG IL10 IL4 LEP
10
Show member pathways
12.25 ICAM1 IFNG IL4 TNF
11
Show member pathways
12.09 IFNG IL10 IL4 TNF
12
Show member pathways
12.08 IFNG IL4 TNF
13 12.05 FCGR2A FCGR3A FCGR3B IFNG IL10 TNF
14 12.03 FCGR2A FCGR3A FCGR3B
15 11.99 ICAM1 IFNG TNF
16 11.98 FCGR3A ICAM1 PVR
17 11.96 FCGR2A FCGR3A FCGR3B IFNG TNF
18 11.91 ICAM1 IL10 IL4 TNF
19 11.87 FCGR2A IFNG IL10 IL4 TNF
20
Show member pathways
11.85 IFNG IL10 TNF
21 11.81 IFNG IL10 TNF
22 11.77 ICAM1 IFNG TNF
23
Show member pathways
11.77 FCGR2A FCGR3A FCGR3B IFNG IL10 IL4
24 11.73 ICAM1 IFNG IL4
25 11.73 IFNG IL10 IL4 TNF
26 11.71 FCGR2A ICAM1 IFNG IL4 LEP TNF
27
Show member pathways
11.69 IFNG IL4 TNF
28 11.67 IFNG IL10 TNF
29
Show member pathways
11.6 ICAM1 IFNG TNF
30 11.5 ICAM1 IL10 IL4 TNF
31 11.49 ICAM1 IFNG IL10 TNF
32 11.44 IFNG IL10 IL4
33 11.4 FCGR2A FCGR3A FCGR3B ICAM1 IL10
34
Show member pathways
11.32 IFNG IL10 TNF
35 11.28 ICAM1 IFNG IL10 TNF
36 11.27 IFNG IL4 TNF
37 11.15 IFNG IL10 IL4
38 11.15 IFNG IL10 IL4 TNF
39 11.08 ICAM1 IFNG
40 11.02 LEP TNF
41 10.99 FCGR2A FCGR3A FCGR3B ICAM1 IL10 IL4
42 10.87 ICAM1 TNF

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 FCGR3B IFNG IL10 IL4 LEP PVR
2 extracellular space GO:0005615 9.23 DPT ICAM1 IFNG IL10 IL4 LEP

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.83 IFNG IL10 IL4 LEP TNF
2 cellular response to lipopolysaccharide GO:0071222 9.79 ICAM1 IL10 TNF
3 regulation of immune response GO:0050776 9.78 FCGR3A ICAM1 IL4 PVR
4 response to insulin GO:0032868 9.72 ICAM1 IL10 LEP
5 regulation of insulin secretion GO:0050796 9.71 IFNG LEP TNF
6 negative regulation of interleukin-6 production GO:0032715 9.64 IL10 TNF
7 positive regulation of protein complex assembly GO:0031334 9.64 IFNG TNF
8 cortical actin cytoskeleton organization GO:0030866 9.63 DLG1 TNF
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.63 IL10 TNF
10 positive regulation of osteoclast differentiation GO:0045672 9.62 IFNG TNF
11 leukocyte tethering or rolling GO:0050901 9.61 LEP TNF
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG TNF
13 negative regulation of growth of symbiont in host GO:0044130 9.6 IL10 TNF
14 negative regulation of glucose import GO:0046325 9.59 LEP TNF
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL10 TNF
16 negative regulation of lipid storage GO:0010888 9.58 LEP TNF
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 ICAM1 IFNG TNF
18 endothelial cell apoptotic process GO:0072577 9.57 IL10 TNF
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IL10 IL4
20 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 ICAM1 TNF
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.51 IL10 TNF
22 type 2 immune response GO:0042092 9.49 IL10 IL4
23 regulation of isotype switching GO:0045191 9.46 IL10 IL4
24 negative regulation of mitotic cell cycle GO:0045930 9.43 DLG1 IL10 TNF
25 receptor biosynthetic process GO:0032800 9.37 IL10 TNF
26 negative regulation of endothelial cell apoptotic process GO:2000352 9.33 ICAM1 IL10 IL4
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
28 immune response GO:0006955 9.1 FCGR3A FCGR3B IFNG IL10 IL4 TNF
29 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 IL10 IL4 LEP
2 cytokine activity GO:0005125 9.26 IFNG IL10 IL4 TNF
3 IgG binding GO:0019864 8.8 FCGR2A FCGR3A FCGR3B

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....